Oncology drugs among most costly to government

Two oncology drugs are among the most costly to the PBS, with biologicals costing hundreds of millions dominating the list of therapies on the $13 billion a year subsidy scheme The PD-1 inhibitor immunotherapy nivolumab (Opdiva) is ranked second  in the 2020 top 10 list of most costly drugs to government, with an annual outlay ...

Already a member?

Login to keep reading.

© 2022 the limbic